Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis

Autoimmunity Reviews

Volumn 17, Issue 7, 2018, Pages 683-693

  Barra, Lillian ^a   Yang, Grace ^a   Pagnoux, Christian ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biologics; Immunosuppressant; Large vessel vasculitis; Takayasu's arteritis; Treatment

Indexed keywords

ABATACEPT; ACUTE PHASE PROTEIN; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORINE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISONE; RESVERATROL; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

AORTIC ARCH SYNDROME; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; EMBASE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMAGING; IMMUNOSUPPRESSIVE TREATMENT; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; PATHOPHYSIOLOGY;

ABATACEPT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OBSERVATIONAL STUDIES AS TOPIC; REMISSION INDUCTION; TAKAYASU ARTERITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85046674572     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2018.01.019     Document Type: Review

References (57)

1. Kerr, G.S., Hallahan, C.W., Giordano, J., Leavitt, R.Y., Fauci, A.S., Rottem, M. et al., Takayasu arteritis. Ann Intern Med 120 (1994), 919–929.
2. Watanabe, Y., Miyata, T., Tanemoto, K., Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: age and sex specificity. Circulation 132 (2015), 1701–1709, 10.1161/CIRCULATIONAHA.114.012547.
3. Yilmaz, N., Can, M., Oner, F.A., Kalfa, M., Emmungil, H., Karadag, O. et al., Impaired quality of life, disability and mental health in Takayasu's arteritis. Rheumatology (Oxford) 52 (2013), 1898–1904, 10.1093/rheumatology/ket238.
4. Schmidt, J., Kermani, T.A., Bacani, A.K., Crowson, C.S., Cooper, L.T., Matteson, E.L. et al., Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 88 (2013), 822–830, 10.1016/j.mayocp.2013.04.025.
5. Mukhtyar, C., Guillevin, L., Cid, M.C., Dasgupta, B., de Groot, K., Gross, W. et al., EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68 (2009), 318–323, 10.1136/ard.2008.088351.
6. Guideline for management of vasculitis syndrome (JCS 2008), Japanese circulation society. Circ J 75 (2011), 474–503.
7. Goel, R., Danda, D., Joseph, G., Ravindran, R., Kumar, S., Jayaseelan, V. et al., Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in southern India. Semin Arthritis Rheum, 2017, 10.1016/j.semarthrit.2017.09.014.
8. Ohigashi, H., Tamura, N., Ebana, Y., Harigai, M., Maejima, Y., Ashikaga, T. et al., Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 69 (2017), 774–778, 10.1016/j.jjcc.2016.07.009.
9. Keser, G., Direskeneli, H., Aksu, K., Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford) 53 (2014), 793–801, 10.1093/rheumatology/ket320.
10. Hozo, S.P., Djulbegovic, B.H.I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 5, 2005, 13.
11. Wells, G.A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M. et al., The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hosp Res Inst, 2013, 1–4.
12. Higgins, J.P.T., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D. et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
13. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M. et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4(1), 2015.
14. Shelhamer, J.H., Volkman, D.J., Parrillo, J.E., Lawley, T.J., Johnston, M.R., Fauci, A.S., Takayasu's arteritis and its therapy. Ann Intern Med 103 (1985), 121–126.
15. Ozen, S., Duzova, A., Bakkaloglu, A., Bilginer, Y., Cil, B.E., Demircin, M. et al., Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr 150 (2007), 72–76, 10.1016/j.jpeds.2006.10.059.
16. Hoffman, G.S., Leavitt, R.Y., Kerr, G.S., Rottem, M., Sneller, M.C., Fauci, A.S., Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37 (1994), 578–582.
17. GY, BK, KA, JL, Response of takayasu arteritis (TA) to prednisolone and methotrexate: an open label study. Indian J Rheumatol, 8, 2013, S27.
18. Kostina, Y.O.L.G., Takaysu arteritis treatment in children. Pediatr Rheumatol, 2014, 2014, 12.
19. Valsakumar, A.K., Valappil, U.C., Jorapur, V., Garg, N., Nityanand, S., Sinha, N., Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30 (2003), 1793–1798.
20. Goel, R., Danda, D., Mathew, J., Edwin, N., Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 29 (2010), 329–332, 10.1007/s10067-009-1333-6.
21. Shinjo, S.K., Pereira, R.M.R., Tizziani, V.A.P., Radu, A.S., Levy-Neto, M., Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 26 (2007), 1871–1875, 10.1007/s10067-007-0596-z.
22. de Souza, A.W.S., da Silva, M.D., Machado, L.S.G., Oliveira, A.C.D., Pinheiro, F.A.G., Sato, E.I., Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41 (2012), 227–230, 10.3109/03009742.2011.633553.
23. Hoffman, G.S., Merkel, P.A., Brasington, R.D., Lenschow, D.J., Liang, P., Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50 (2004), 2296–2304, 10.1002/art.20300.
24. Molloy, E.S., Langford, C.A., Clark, T.M., Gota, C.E., Hoffman, G.S., Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67 (2008), 1567–1569, 10.1136/ard.2008.093260.
25. Mekinian, A., Neel, A., Sibilia, J., Cohen, P., Connault, J., Lambert, M. et al., Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 51 (2012), 882–886, 10.1093/rheumatology/ker380.
26. Schmidt, J., Kermani, T.A., Bacani, A.K., Crowson, C.S., Matteson, E.L., Warrington, K.J., Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res 64 (2012), 1079–1083, 10.1002/acr.21636.
27. Comarmond, C., Plaisier, E., Dahan, K., Mirault, T., Emmerich, J., Amoura, Z. et al., Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 11 (2012), 678–684, 10.1016/j.autrev.2011.11.025.
28. Novikov, P.I., Smitienko, I.O., Moiseev, S.V., Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 32 (2013), 1827–1832, 10.1007/s10067-013-2380-6.
29. Quartuccio, L., Schiavon, F., Zuliani, F., Carraro, V., Catarsi, E., Tavoni, A.G. et al., Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 30 (2012), 922–928.
30. T, E., B, E., F, S., M, F., A, P., Csd, G., Efficacy of anti-TNF therapy in 15 patients with refractory takayasu's arteritis: long term unicentric follow-up. Ann Rheum Dis, 71, 2013, 10.1136/annrheumdis-2012-eular.2174.
31. Serra, R., Grande, R., Buffone, G., Scarcello, E., Tripodi, F., Rende, P. et al., Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J Pharmacol Pharmacother 5 (2014), 193–196, 10.4103/0976-500X.136101.
32. Mekinian, A., Comarmond, C., Resche-Rigon, M., Mirault, T., Kahn, J.E., Lambert, M. et al., Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation 132 (2015), 1693–1700, 10.1161/CIRCULATIONAHA.114.014321.
33. Gudbrandsson, B., Molberg, O., Palm, O., TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther, 19, 2017, 99, 10.1186/s13075-017-1316-y.
34. NP, SI, ZE, EA, MS, Retrospective study of biologic agents in Takayasu arteritis. Rheumatol (United Kingdom), 2017, 56.
35. Abisror, N., Mekinian, A., Lavigne, C., Vandenhende, M.-A., Soussan, M., Fain, O., Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 12 (2013), 1143–1149, 10.1016/j.autrev.2013.06.019.
36. Tombetti, E., Franchini, S., Papa, M., Sabbadini, M.G., Baldissera, E., Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 40 (2013), 2047–2051, 10.3899/jrheum.130536.
37. Yamazaki, K., Kikuchi, M., Nozawa, T., Kanetaka, T., Hara, R., Imagawa, T. et al., Tocillizumab for patients with takayasu arteritis in childhood refractory to conventional therapy. Pediatr Rheumatol, 2013, 11.
38. Canas, C.A., Canas, F., Izquierdo, J.H., Echeverri, A.-F., Mejia, M., Bonilla-Abadia, F. et al., Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 20 (2014), 125–129, 10.1097/RHU.0000000000000098.
39. Loricera, J., Blanco, R., Hernandez, J.L., Castaneda, S., Humbria, A., Ortego, N. et al., Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 34 (2016), S44–53.
40. Zhou, J., Chen, Z., Li, J., Yang, Y., Zhao, J., Chen, H. et al., The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. Clin Exp Rheumatol 35:Suppl. 1 (2017), 171–175.
41. Goel, R.S.G., Long term outcome of tocilizumab therapy for management of Takayasu arteritis. Indian J Rheumatol, 12, 2017, S15.
42. Pazzola, G., Muratore, F., Pipitone, N., Crescentini, F., Cacoub, P., Boiardi, L. et al., Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford), 2017, 10.1093/rheumatology/kex249.
43. BSBAZDDF, R., NP, HM, KS, Takayasu, S., Arteritis: clinical features and treatment outcome in 16 pediatric patients. Clin Exp Rheumatol, 29, 2011, 403.
44. Shao, N., Jia, H., Li, Y., Li, J., Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-alpha: a randomized placebo-controlled double-blind clinical trial. Immunol Res 65 (2017), 969–974, 10.1007/s12026-017-8917-z.
45. Shi, G., Hua, M., Xu, Q., Ren, T., Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: a randomized double-blind and placebo-controlled trial. Immunobiology 222 (2017), 164–168, 10.1016/j.imbio.2016.10.008.
46. Langford, C.A., Cuthbertson, D., Ytterberg, S.R., Khalidi, N., Monach, P.A., Carette, S. et al., A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol (Hoboken, NJ) 69 (2017), 846–853, 10.1002/art.40037.
47. Nakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S. et al., Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis, 2017, 10.1136/annrheumdis-2017-211878.
48. B, S., B, A., Z, D., D, F., N, P., H, M. et al., Takayasu arteritis: clinical features and treatment outcome in 16 pediatric patients. Clin Exp Rheumatol, 29, 2011, 403.
49. Goel, R., Danda, D., Kumar, S., Joseph, G., Rapid control of disease activity by tocilizumab in 10 “difficult-to-treat” cases of Takayasu arteritis. Int J Rheum Dis 16 (2013), 754–761, 10.1111/1756-185X.12220.
50. Luqmani, R.A., Bacon, P.A., Moots, R.J., Janssen, B.A., Pall, A., Emery, P. et al., Birmingham Vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 87 (1994), 671–678.
51. Barra, L., Liang, P., Benseler, S.M., Cabral, D.A., Fifi-Mah, A., Li, Y. et al., Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey. Open Access Rheumatol Res Rev 9 (2017), 91–99, 10.2147/OARRR.S132080.
52. Aeschlimann, F.A., Eng, S.W.M., Sheikh, S., Laxer, R.M., Hebert, D., Noone, D. et al., Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Res Ther, 19, 2017, 255, 10.1186/s13075-017-1452-4.
53. Terao, C., Yoshifuji, H., Nakajima, T., Yukawa, N., Matsuda, F., Mimori, T., Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol 45 (2016), 80–82, 10.3109/03009742.2015.1060521.
54. Aydin, S.Z., Merkel, P.A., Direskeneli, H., Outcome measures for Takayasu's arteritis. Curr Opin Rheumatol 27 (2015), 32–37, 10.1097/BOR.0000000000000129.
55. Barra, L., Kanji, T., Malette, J., Pagnoux, C., Vasc, C., Imaging modalities for the diagnosis and disease activity assessment of Takayasu's arteritis: a systematic review and meta-analysis. Autoimmun Rev, 2017, 10.1016/j.autrev.2017.11.021.
56. Misra, R., Danda, D., Rajappa, S.M., Ghosh, A., Gupta, R., Mahendranath, K.M. et al., Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010). Rheumatology (Oxford) 52 (2013), 1795–1801, 10.1093/rheumatology/ket128.
57. Sreih, A.G., Alibaz-Oner, F., Kermani, T.A., Aydin, S.Z., Cronholm, P.F., Davis, T. et al., Development of a Core set of outcome measures for large-vessel Vasculitis: report from OMERACT 2016. J Rheumatol 44 (2017), 1933–1937, 10.3899/jrheum.161467.